BeOne Medicines AG
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ONC | 688759.SS | 6855.HK | 688382.SS | GMAB | 0A3M.IL | |
|---|---|---|---|---|---|---|
| Market cap | 42.98B | 7.56B | 11.30B | 8.38B | 33.89B | 25.17B |
| P/E (TTM) | 67.6 | — | — | — | 43.4 | 5.1 |
| Forward P/E | 36.2 | — | -78.0 | -43.8 | 34.9 | 5.1 |
| Price/book | 8.3 | 4.9 | 17.3 | 6.6 | 5.5 | 1.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +13.67% | −52.52% | −56.77% | −48.70% | +91.12% | −13.17% |
| Today | +6.42% | +4.42% | +6.70% | +4.33% | −0.72% | +2.81% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ONC news ›Beximco Pharma posts record Tk916 crore profit in FY26
Friday October 30, 2026 Beximco Pharmaceuticals PLC, one of the country's largest drugmakers, reported a record consolidated net profit of Tk916.08 crore for FY26, up 31% from Tk699.89 crore in the previous fiscal year. According to…
pembrolizumab/berahyaluronidase (Rx)
Medscape - Cancer dosing for Keytruda Qlex (pembrolizumab/berahyaluronidase), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information.
BeOne Medicines: Brukinsa And Tevimbra Face A High Bar
BeOne Medicines AG’s oncology growth is fueled by Tevimbra and a deep pipeline, but its premium valuation tempers upside. Click for more on ONC stock. - BeOne Medicines AG is a fast-growing oncology company and a Wall Street favorite. -…
BeOne Medicines (ONC) Liver Cancer Drug Achieves 36% Response in Early Trial Data
BeOne Medicines AG, ONC BeOne Medicines shared refreshed Phase 1 data for BGB-B2033, a novel agent developed for patients with advanced hepatocellular carcinoma. The therapy produced a 36% confirmed objective response rate when…
BeOne Stock Breaks Out With Visions Of 177% Earnings Growth. This Telltale Clue Bodes Well.
With Investor's Business Daily since 2003, Galgani's role entails working with IBD's writers and editors to help maximize engagement with readers across all platforms, as well as helping manage IBD's social media accounts. The author of…
BeOne Medicines (NASDAQ:ONC) Hits New 52-Week High – Should You Buy?
Posted by Kim Johansen on Oct 21st, 2026 BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) shares hit a new 52-week high on Wednesday. The stock traded as high as $386.87 and last traded at $386.2450, with a volume of…
BeOne Medicines director sells 31,027 depositary shares
3 E Network Signs Core 9 MVA Power Distribution Agreement for Mikkeli AI Compute Center in Finland J-Star Holding Co., Ltd. Advances U.S. Drone Manufacturing Initiative; Negotiates Acquisition of Facility in the Greater Houston Area Merck…
BeOne Medicines counsel Chan Henry Lee sells shares
SCWorx Announces New Agreement with Healthcare System Lianhe Sowell International Group Ltd. Secures RMB23.84 Million Order for 80 AI Spray Painting Robots in Malaysia and First UK Order Iovance Highlights TIL Cell Therapy Platform Across…
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
BeOne Medicines (ONC) will present solid tumor pipeline and TEVIMBRA data at the ESMO Congress on October 23–27, 2026, in Madrid. New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4…
BeOne Medicines (NASDAQ:ONC) Insider Sells $10,890,166.73 in Stock
Posted by Defense World Staff on Oct 18th, 2026 Xiaodong Wang also recently made the following trade(s): Get Our Latest Report on ONC BeOne Medicines Ltd. (NASDAQ: ONC) is a global oncology company focused on discovering, developing,…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketbeat.com3
- themarketsdaily.com3
- marketscreener.com2
- stocktitan.net2
- contractpharma.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 20 articles, not a forecast.